Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Prudential Ups Onyx Pharma to Overweight

From Standard & Poor's Equity Research

Prudential upgraded Onyx Pharmaceuticals (ONXX) to overweight from neutral, explaining that the shares have fallen to attractive levels.

Analyst Jason Zhang says imminent news flow after the annual meeting of American Society of Clinical Oncology (ASCO) should be positive to shareholders. He notes that Onyx shares began 2006 in the $30-range and are now near $20. But during this period, the company has made significant progress in successfully launching Nexavar and reporting $25 million in first quarter sales, above Street expectations. He ties recent weakness in the stock to concerns about a Nexavar competitor, and thinks any further downside risk is limited.

blog comments powered by Disqus